US2012115878A1PendingUtilityA1
Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Est. expiryNov 10, 2030(~4.3 yrs left)· nominal 20-yr term from priority
A61P 37/06A61P 35/02A61P 35/00A61P 43/00C07D 401/12C07D 487/04A61K 31/519C07D 213/75C07D 213/74C07D 239/42C07D 401/04C07D 213/73C07C 55/10C07D 213/72
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
Claims
exact text as granted — not AI-modified1 . Succinate salt of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide.
2 . The salt of claim 1 , wherein the salt is described by Formula (II)
3 . The salt of claim 1 in a non-hydrate form.
4 . The salt of claim 1 in a hydrate form.
5 . A pharmaceutical composition comprising:
(a) a therapeutically effective amount of a salt according to any of claim 1 ; and (b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient.
6 . A method of treating a disease which responds to an inhibition of cyclin dependent kinases activity comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a salt according to claim 1 .
7 . A method of preparing the compound of Formula (I) comprising
(2) converting the
8 . The method of claim 7 , wherein step (1) is performed in the presence of Pd(OAc) 2 , BINAP, and Cs 2 CO 3 .
9 . The method of claim 7 , wherein step (2) is performed in the presence of HCl(aq.) and toluene.
10 . The method of claim 7 , wherein the
is further converted to
11 . The method of claim 10 where in the conversion takes place in the presence of IPA and
12 . A method of preparing the compound of Formula (III):
comprising converting
13 . The method of claim 12 , wherein the conversion of the
takes place in the presence of MnO 2 , NaCN,
and THF.
14 . The method of claim 12 wherein the
is formed from
15 . A method of preparing the compound of Formula (III):
comprising:
16 . A method of preparing the compound of Formula (IV):
comprising
17 . The method of claim 16 wherein the reaction takes place in the presents of n-BuOH.
18 . A method of preparing the compound of Formula (IV):
comprising:Join the waitlist — get patent alerts
Track US2012115878A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.